By reducing IGF2 production by removing the tumour (if this is surgically possible) or by temporarily increasing IGF-BP3 production by exogenous growth hormone administration (Fig. 20.22), the hypoglycaemia of NICTH may be relieved sufficiently to make surgery possible or to improve the quality of the remaining life of the patient.
